Catalyst Wire Dossier Catalyst Wire Dossier

Gilotrif (afatinib)

afatinib · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Gilotrif (afatinib), covering 2013-12-23 to 2025-03-28. Get the full timeline:

Most recent: Clinical Trial Update: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors [Phase 2]

See pricing